Abstract:Aminopeptidases hydrolyze the N-terminal amino acid of proteins or peptide substrates. Among them, the M1 family of zinc aminopeptidases (gluzincins) shares the consensus GAMEN and HEXXH(X) 18 E motifs essential for enzymatic activity. This family, which consists of 11 enzymes in humans, [1][2][3] plays important roles in several pathophysiological processes, such as angiogenesis, cell cycle regulation, reproduction, memory retention, blood pressure control, and antigen presentation to major histocompatibility… Show more
Endoplasmic reticulum aminopeptidases ERAP1/2 have emerged in the last years as key enzymes for the production of antigenic peptides that are presented by MHC class I molecules at the cell surface as part of the adaptive immune response. ERAP1 has unusual enzymatic properties that make it particularly suitable for this biological function. Specifically, it efficiently degrades peptides longer than 9 residues and shows preferences for the whole substrate sequence and not only for the N-terminus. Recently, coding Single Nucleotide Polymorphisms (SNPs) in ERAP1/2 were associated with predisposition to autoimmune diseases, such as ankylosing spondylitis, with cancer and with resistance to HIV infection. The hypothesis of this thesis is that the particular molecular mechanism of action of ERAP1/2 and the way in which this mechanism is affected by coding polymorphisms is the underlying reason for the association of ERAP1/2 with predisposition to human disease. To verify this hypothesis we investigated the molecular mechanism of action of ERAP1/2 aminopeptidases in the context of their polymorphic variability. We first developed a novel fluorigenic assay to analyze the activity of these enzymes. Biochemical analysis in combination with the recently solved ERAP1 crystal structure allowed us to propose a molecular model of function that can account for both substrate length and sequence specificity. In parallel, we set the groundwork for the development of small molecular weight compounds that modulate ERAP1 activity, by scanning a chemical library of pharmaceuticals and discovering lead compounds that either act as inhibitors or as activators of the enzyme.In order to understand the association of ERAP1/2 polymorphicity with changes in antigen presentation, we expressed different ERAP1/2 alleles and studied their ability to degrade different antigenic epitope precursors. Michaelis-Menten analysis showed that specific SNPs in ERAP1 affect the ΚΜ and kcat parameters of the enzyme and that particular allele-substrate combinations demonstrate substrate inhibition kinetics. A common ERAP2 allele was found to have a stronger effect on enzyme function and, as ERAP1 alleles, not only affects enzymatic activity but also alters specificity. The above results support the hypothesis that genetic variability in ERAP1/2 aminopeptidases can affect the generation of antigenic epitopes and may represent a previously unrecognized facet of adaptive immune response variability.
Endoplasmic reticulum aminopeptidases ERAP1/2 have emerged in the last years as key enzymes for the production of antigenic peptides that are presented by MHC class I molecules at the cell surface as part of the adaptive immune response. ERAP1 has unusual enzymatic properties that make it particularly suitable for this biological function. Specifically, it efficiently degrades peptides longer than 9 residues and shows preferences for the whole substrate sequence and not only for the N-terminus. Recently, coding Single Nucleotide Polymorphisms (SNPs) in ERAP1/2 were associated with predisposition to autoimmune diseases, such as ankylosing spondylitis, with cancer and with resistance to HIV infection. The hypothesis of this thesis is that the particular molecular mechanism of action of ERAP1/2 and the way in which this mechanism is affected by coding polymorphisms is the underlying reason for the association of ERAP1/2 with predisposition to human disease. To verify this hypothesis we investigated the molecular mechanism of action of ERAP1/2 aminopeptidases in the context of their polymorphic variability. We first developed a novel fluorigenic assay to analyze the activity of these enzymes. Biochemical analysis in combination with the recently solved ERAP1 crystal structure allowed us to propose a molecular model of function that can account for both substrate length and sequence specificity. In parallel, we set the groundwork for the development of small molecular weight compounds that modulate ERAP1 activity, by scanning a chemical library of pharmaceuticals and discovering lead compounds that either act as inhibitors or as activators of the enzyme.In order to understand the association of ERAP1/2 polymorphicity with changes in antigen presentation, we expressed different ERAP1/2 alleles and studied their ability to degrade different antigenic epitope precursors. Michaelis-Menten analysis showed that specific SNPs in ERAP1 affect the ΚΜ and kcat parameters of the enzyme and that particular allele-substrate combinations demonstrate substrate inhibition kinetics. A common ERAP2 allele was found to have a stronger effect on enzyme function and, as ERAP1 alleles, not only affects enzymatic activity but also alters specificity. The above results support the hypothesis that genetic variability in ERAP1/2 aminopeptidases can affect the generation of antigenic epitopes and may represent a previously unrecognized facet of adaptive immune response variability.
Summary
It is now evident that the M1 family of aminopeptidases play important roles in many pathophysiological processes. Among them, the enzymatic properties of Arginyl aminopeptidase-like 1 (RNPEPL1) are characterized only by its truncated form. No peptide substrate has been identified. To characterize the enzymatic properties of RNPEPL1 in more detail, the full-length protein was expressed in E. coli and purified to homogeneity. The full-length RNPEPL1 showed rather restricted substrate specificity and basic amino acid preference toward synthetic substrates, which was different from the previously reported specificity characterized by the truncated form. Searching for peptide substrates, we found that several peptides, such as Met-enkephalin and kallidin, were cleaved. RNPEPL1 cleaved bradykinin to de-[Arg]-bradykinin despite the presence of proline at the P2’-position. The enzyme cleaved Met-enkephalin but not dynorphin A1-17. Similar to aminopeptidase B, the full-length RNPEPL1 showed basic amino acid preference toward both synthetic and peptide substrates. In addition to the unusual cleavage of bradykinin, this enzyme shows chain-length-dependent cleavage of peptide substrates sharing N-terminal amino acid sequence. This is the first study to report the enzymatic properties of the full-length human RNPEPL1 as an aminopeptidase enzyme.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.